Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs

Wennan Li¹ · Xingjuan Chen¹ · Ashley M. Riley¹ · S. Christopher Hiett¹ · Constance J. Temm² · Eleni Beli⁴ · Xin Long¹ · Saikat Chakraborty¹ · Mouhammad Alloosh¹ · Fletcher A. White³ · Maria B. Grant¹,⁴ · Michael Sturek¹ · Alexander G. Obukhov¹

Received: 28 November 2016 / Revised: 17 July 2017 / Accepted: 24 July 2017 / Published online: 29 July 2017
© The Author(s) 2017. This article is an open access publication

Abstract Coronary transient receptor potential canonical (TRPC) channel expression is elevated in metabolic syndrome (MetS). However, differential contribution of TRPCs to coronary pathology in MetS is not fully elucidated. We investigated the roles of TRPC1 and TRPC6 isoforms in coronary arteries of MetS pigs and determined whether long-term treatment with a mineralocorticoid receptor inhibitor, spironolactone, attenuates coronary TRPC expression and associated dysfunctions. MetS coronary arteries exhibited significant atherosclerosis, endothelial dysfunction, and increased histamine-induced contractions. Immunohistochemical studies revealed that TRPC6 immunostaining was significantly greater in the medial layer of MetS pig coronary arteries compared to that in Lean pigs, whereas little TRPC6 immunostaining was found in atheromas. Conversely, TRPC1 immunostaining was weak in the medial layer but strong in MetS atheromas, where it was predominantly localized to macrophages. Spironolactone treatment significantly decreased coronary TRPC expression and dysfunctions in MetS pigs. In vivo targeted delivery of the dominant-negative (DN)-TRPC6 cDNA to the coronary wall reduced histamine-induced calcium transients in the MetS coronary artery medial layer, implying a role for TRPC6 in mediating calcium influx in MetS coronary smooth muscles. Monocyte adhesion was increased in Lean pig coronary arteries cultured in the presence of aldosterone; and spironolactone antagonized this effect, suggesting that coronary mineralocorticoid receptor activation may regulate macrophage infiltration. TRPC1 expression in atheroma macrophages was associated with advanced atherosclerosis, whereas medial TRPC6 upregulation correlated with increased histamine-induced calcium transients and coronary contractility. We propose that long-term spironolactone treatment may be a therapeutic strategy to decrease TRPC expression and coronary pathology associated with MetS.

Keywords Coronary artery · Metabolic syndrome · Atherosclerosis · Spironolactone · TRPC

Introduction

Metabolic syndrome (MetS) is a condition characterized by central obesity, insulin resistance, glucose intolerance, dyslipidemia, hypertension, and atherosclerosis [23, 38, 50]. Atherosclerosis usually occurs in the large and medium-sized arteries [19]. Atherosclerotic plaques are made of lipids, cholesterol, extracellular matrix deposits, proliferating smooth muscle cells (SMCs), T-lymphocytes, foam cells, and macrophages. These lesions decrease the vessel lumen area and cause obstruction of blood flow.
Furthermore, atherosclerotic coronary arteries exhibit increased spasticity [46, 49] that may lead to angina, myocardial infarction, and sudden death [27].

Angina patients present with elevated plasma histamine concentration [43], indicating that histamine-induced coronary artery contractions may contribute to some ischemic episodes in these patients. Indeed, histamine is known to contract coronary arteries, with the presence of atherosclerosis potentiating the contractile response [11, 22]. In the coronary circulation, histamine mainly originates from mast cells infiltrating atherosclerotic lesions [47]; and mast cells are often found at the site of coronary spasm in the patients with angina [18]. In turn, histamine is an activator of transient receptor potential canonical (TRPC) calcium-permeable cation channels [10, 12, 41], which are expressed in vascular SMCs. TRPC channels are implicated in the pathogenesis of hypertension and neointimal hyperplasia [1, 33, 40].

One of the features of MetS is elevated plasma aldosterone [6, 13, 32]. Aldosterone is an agonist of the mineralocorticoid receptor, which is widely expressed in the kidney, heart, and vasculature [29, 37]. Elevated aldosterone may induce extracellular matrix remodeling by enhancing collagen synthesis, fibrosis, and vascular inflammation [5, 36] and is considered a risk factor for heart failure, myocardial infarction, stroke, and coronary artery disease [25, 28, 35]. Indeed, both human and animal studies have shown that aldosterone may be involved in facilitating atherosclerosis development [15, 20, 25, 31, 37].

Our previous study showed that TRPC1 and TRPC6 expression is increased in coronary arteries from MetS pigs as compared to Lean pigs [16]. We also reported that aldosterone, acting via the mineralocorticoid receptor, increased TRPC1 and TRPC6 expression in the adrenal medulla of MetS pigs [26] exhibiting elevated plasma aldosterone [2]. Consistently, Bae et al. reported that mineralocorticoids enhance TRPC6 expression in rat aortic smooth muscle cells [3]. In this study, we investigated the roles of TRPC1 and TRPC6 channels in the coronary artery of MetS pigs and whether long-term inhibition of the mineralocorticoid receptor by spironolactone downregulates coronary TRPC expression and attenuates MetS-induced coronary pathology.

Materials and methods

Animals

Thirty-six castrated Ossabaw miniature pigs were subdivided into three groups: Lean, metabolic syndrome (MetS), and metabolic syndrome treated with spironolactone (MetS-SN). The pigs were initially fed with the standard chow consisting of 22% kcal from protein, 70% kcal from carbohydrates, and 8% kcal from fat (5L80 diet, Purina Test Diet, Richmond, IN, USA) until an age of 6–8 months. Then, the Lean group of pigs was maintained on the same standard chow for an additional 7–9 months. The MetS group of pigs was fed with an atherogenic diet, consisting of 16% kcal from protein, 21% kcal from mixed carbohydrates, 20% kcal from fructose, and 43% kcal from fat, which was supplemented with 2% cholesterol and 0.7% sodium cholate by weight (KT324 diet, Purina Test Diet, Richmond, IN, USA; 1 kg/day) for 7–9 months, similar to previous reports [16]. The pigs from the MetS-SN group were fed the atherogenic KT324 diet (1 kg/day) mixed with spironolactone (3 mg/kg body weight/day). During this study, two out of 13 investigated MetS pigs prematurely died. Postmortem histological assessment indicated that these two pigs had very advanced atherosclerosis, suggesting that the pigs had likely died due to a myocardial infarction. In contrast, no deaths occurred in the Lean (14 pigs) or MetS-SN (9 pigs) groups.

Intravenous glucose tolerance test (IVGTT)

Prior to the test, pigs were acclimated to a canvas sling, which was used to suspend a pig above the ground, for 30–60 min daily for 3–5 days. A day before an IVGTT, the central venous catheter (Cook Medical, Bloomington, IN, USA) was percutaneously placed into the jugular vein under isoflurane anesthesia and secured on the lateral side of the neck for future blood sampling. All pigs were fasted overnight before IVGTTs, and the tests were performed without anesthesia because it artificially elevates blood glucose concentration. A single dose of 1 g glucose/kg body weight was given at a time of zero through the central venous catheter. Then, ~3 ml blood samples were collected every 10 min for 60 min via the same catheter to assess glucose tolerance. Blood samples were centrifuged at 2000 rpm for 20 min at 4 °C to collect blood serum; serum glucose concentration was determined using an YSI 2300 STAT plus Glucose analyzer (YSI Life Sciences., Yellow Springs, OH, USA).

Intravascular ultrasound (IVUS)

Ceftiofur (5 mg/kg, IM) and aspirin (300 mg) were given to pigs on the day of the procedure. Anesthesia induction was carried out using an intramuscular injection of a mixture of telazol (5 mg/kg) and xylazine (3 mg/kg) that was followed by isoflurane endotracheally (2–4% mixed with 100% O2) to maintain anesthesia. The anesthetized, heparinized, and intubated unconscious animal was secured in a supine position, and a subcutaneous injection of a
mixture of topical anesthetics (2% lidocaine and 2% bupivacaine; 50:50) was given before the surgery. The arterial sheath introducer (7 F introducer sheath, Boston Scientific, Marlborough, MA, USA) was placed into the right femoral artery through an arteriotomy. Using X-ray angiography to monitor the progress of placements, the guiding catheter (7 F guide catheter, Mach1, HS SH, AL.75 SH, Boston Scientific) engaged the coronary ostium and then an angioplasty guidewire was deployed into a coronary artery. A contrast solution injection (OMNIpaque, GE healthcare, Princeton, NJ, USA) was used to visualize the coronary artery tree. Then, the Revolution 45 MHz Rotational Imaging Intravascular Ultrasound Catheter-transducer (Volcano Inc, Rancho Cordova, CA, USA) was advanced along the guide wire to the distal part of the coronary artery and the pullback of the IVUS transducer was performed at 0.5 mm/s. Cross-sectional IVUS images were acquired every 2 mm through the ~40 mm length of coronary arteries. The plaque wall coverage was measured using the Image-Pro Premier 9.1 software package (Media Cybernetics Inc., Warrendale, PA, USA) to determine the extent of atherosclerosis. Percent wall coverage (% wall coverage) was calculated as the length of plaque-covered coronary artery wall segment divided by the coronary artery perimeter and multiplied by 100. The wall coverage data from 20 images for each individual right coronary artery (RCA) and left anterior descending (LAD) coronary artery of a pig were averaged to represent the mean wall coverage value for the pig. Then the mean wall coverage for each treatment group was calculated by averaging the mean wall coverage data obtained in each pig.

**Masson’s trichrome staining and immunohistochemistry**

Freshly isolated coronary arteries were cut into 3 mm cross-sectioned rings, fixed in 10% phosphate-buffered formalin (Fisher Scientific, Fair Lawn, NJ, USA), and then embedded in paraffin. Paraffin blocks were cut into 5 µm thick sections, which were de-paraffinized and rehydrated after mounting on glass slides. Masson’s trichrome staining was performed using the DAKO Masson’s Trichrome Stain kit on the Artisan™ Link Special Stains Instrument (Dako North America, Inc., Agilent Technologies, Carpinetaria, CA, USA). Collagen in the coronary wall stained blue and SMCs stained red. Collagen content measurements were performed within the entire medial layer and atheroma. Hematoxylin and eosin (H&E) staining was performed using the H&E Staining Kits from Tissue-Tek® Prisma® Automated Slide Stainers. Sections were examined using a Nikon microscope. Images were taken randomly from at least four different areas of the ring at 4× or 20× magnification. Image-Pro was used to quantify the positive staining. Results were expressed as a percentage of blue collagen staining over total area in the medial layer or the atheroma.

Immunostaining was performed using the following antibodies: the α-smooth muscle actin antibody (dilution 1:50, α-SMA, human, Sigma, St. Louis, MO, USA), the TRPC1 antibody (dilution 1:50, gift from Dr. Tsiokas), the TRPC6 antibody (dilution 1:25, S-20, Santa Cruz Biotechnology, Dallas, TX, USA), the CD163 antibody (1:100, Vector, Burlingham, CA, USA), the CD4 antibody (ready-to-use, IR649, DAKO, Glostrup, Denmark), and the CD33 antibody (ready-to-use, PWS44, Cell Marque, Rocklin, CA, USA). After incubations with the primary antibodies at room temperature, the sections were then probed using the DAKO Flex system (SMA, CD163, and CD4), the DAKO Omnis (CD33), the DAKO Envision + mouse (TRPC1) or with the secondary biotin AffiniPure donkey anti-goat antibody for TRPC6 (dilution factor 1:100, The Jackson ImmunoResearch Laboratory, West Grove, PA, USA), followed by the DAKO LSAB2 horseradish peroxidase-conjugated polymer. All washes were made using the DAKO wash buffer. The brown color was developed using diaminobenzidine. The staining density was quantified using the DAB analysis module of Image-Pro Premier 9.1 (Media Cybernetics Inc., Warrendale, PA, USA). The specific staining is reported after normalization to adventitia background staining density.

**In vivo gene delivery**

A micro-infusion Bullfrog catheter [21] (Mercator Medsystems, San Leandro, CA, USA) was used to deliver the cDNA into the coronary artery wall and a custom made intravascular electroporation catheter [45] (Cardigant Medical Inc., Manhattan Beach, CA, USA) to transiently electropermeabilize SMCs, allowing their loading with cDNA. Since both catheters were designed for 3 mm arteries, before performing an in vivo gene delivery procedure, a coronary artery segment of 3 mm diameter was identified using IVUS. The segment chosen was a site that was close to a prominent coronary artery branch. This allowed identification of the segment following dissection. After completing the IVUS procedure, the IVUS catheter was withdrawn from the coronary artery and the micro-infusion Bullfrog catheter was advanced into the same artery under angiographic guidance to the selected artery segment. The 130 µm diameter injecting needle was deployed into the coronary vascular wall, and an injection of 0.7–1 ml of 1 mg/ml dominant-negative (DN) pig TRPC6 (L645A/F646A/W647A) cDNA in the pcDNA3.1 vector or the empty vector in sterile NaCl solution was performed. The needle was retracted and the injection
catheter was withdrawn. The intravascular electroporation catheter was deployed to the site of injection and in vivo electroporation was performed using three square 20 ms voltage pulses of 75 V with an interval of 1 s. After the intra-coronary intervention was completed, the catheters and the guide wire were withdrawn and the incision was sutured. Aspirin (300 mg) was given to the pig by mouth with the feed a day before and a day after surgery. The expression of DN-TRPC6 was driven with the human cytomegalovirus immediate-early promoter of the pcDNA3.1 vector. The in vivo electroporated pigs were euthanized 48 h after the in vivo cDNA delivery procedure.

**Isometric tension measurement**

Isolated coronary arteries were cut into 2–3 mm rings and mounted in the organ baths containing Krebs solution saturated with a gas mixture of 95% O2 and 5% CO2 at 37 °C. The optimal length was determined as described elsewhere [8, 11, 24]. This usually resulted in a preload value of ~3 g. Both KCl and histamine were added directly to the organ baths. The standard Krebs buffer contained (mM): 131.5 NaCl, 5 KCl, 2.5 CaCl2, 1.2 NaH2PO4, 1.2 MgCl2, 25 NaHCO3, and 10 glucose. Vessel tensions were measured using a GlobalTown Microtechnology (Sarasota, FL, USA) wire myograph. Active tension was determined as the difference of the peak and baseline tension.

**Front-surface fluorometry in coronary artery rings**

A monochromator-equipped imaging system (TILL-Photonics, Martinsried, Germany) was used to monitor intracellular Ca2+ changes in coronary artery rings. Cross-sectioned rings (~1 mm thick) were loaded with fura-2 by incubating with 8 μM fura-2AM (Molecular Probes, Inc., Eugene, OR, USA) for 6–10 h in a phosphate-buffered saline (DPBS, Cat # 14287, ThermoFisher Scientific, Waltham, MA, USA) solution containing 0.9 mM Ca2+, 0.49 Mg2+, supplemented with 5.5 mM D-glucose, 0.33 mM sodium pyruvate, and 2% bovine serum albumin (BSA), at room temperature in the dark. Rings were washed three times with PBS without fura-2AM and incubated in solutions without fluorescent dye for additional 30–60 min at room temperature. Fura-2 fluorescence was induced by alternating excitation at 345 and 380 nm. The obtained data were analyzed using TILLvisION software. The background fluorescence measured in a ring free area was subtracted from all fluorescence values before the determination of the F345/F380 ratio. The peak amplitudes of KCl and histamine were determined by subtracting the baseline ratio. The histamine steady state amplitude values were measured at the time point of 3.3 min after the histamine response peaked. The standard extracellular solution for fluorescence measurements contained (mM): 140 NaCl, 2.5 KCl, 1 MgCl2, 5 CaCl2, 4 glucose, 10 HEPES (pH 7.2).

**Preparation of porcine peripheral blood mononuclear cells (PBMCs) and enrichment of monocytes**

Porcine blood was collected in sodium heparin-containing tubes and immediately used for PBMC isolation with Ficoll-Paque PLUS (GE Healthcare Bio-Sciences, PA, USA) according to instructions by the manufacturer. 10 million PBMCs cells were stained with PerCP/Cy5.5 Anti-Pig CD3ε (12 mg/ml, clone: BB23-8E6-8c8, BD Pharmingen) and R-phycocerythrin Anti-Pig CD79a (8 mg/ml, clone: HM47, eBioscience) antibodies and then sorted on the BD SORP Aria instrument. The stained PBMCs were first gated with high Forward Scatter (FSC-A) and high Side-Scatter (SSC-A) of light to collect monocyte subpopulations, which were further sorted to exclude the cells positive for CD3ε and CD79a. Enrichment was assessed by staining the initial PBMC samples and sorted monocyte samples with fluorescence isothiocyanate anti-pig monocyte/ granulocytes CD172a (10 mg/ml, clone 74-2215A, BD Pharmingen) and PerCP/Cy5.5 anti-pig CD3ε antibodies. The monocyte enrichment was 77–82% (n = 4).

**Coronary artery organ-culture**

Lean pig coronary arteries (3 mm long strips or rings) were pretreated for 2–7 days with either vehicle (DMSO), aldosterone (100 nM), a mixture of aldosterone and spironolactone (100 nM and 10 μM, respectively), or spironolactone (10 μM) in EMEM (cat # 30-2003, ATCC, Manassas, VA, USA) supplemented with 2% bovine serum albumin, 50 units penicillin, and 50 μg/ml streptomycin. The medium was replaced daily. Organ-cultured coronary artery segments were maintained at 37 °C in a water-jacketed 5% CO2 incubator.

**Monocyte adhesion assay**

Organ-cultured coronary artery strips were treated with vehicle (DMSO), aldosterone (100 nM), a mixture of aldosterone and spironolactone (100 nM and 10 μM, respectively), or spironolactone (10 μM) for 48 h. The isolated pig peripheral blood monocytes were loaded with Carboxy SNARF-1 (10 μM, Spiro[7H-benzo [c]xanthene-7,1’(3H)-isobenzofuran]-ar’-carboxylic acid, 3-(acetyloxy)-10-(dimethylamino)-3’-oxo-, (acetyloxy)methyl ester; ThermoFisher Scientific) for 30 min at room temperature.
The SNARF-1 loaded monocytes \((3 \times 10^4 - 2 \times 10^5\) cells per well) were added to the four listed above groups of treated organ-cultured strips and incubated for 2 h at 37 °C on the stage of a horizontal New Brunswick Scientific Shaker, rotating at 75 rpm in the atmosphere of 5% CO\(_2\) and 95% oxygen. After the incubation period, the strips were gently washed three times with PBS supplemented with Ca\(^{2+}\), Mg\(^{2+}\), glucose, and pyruvate (catalog # 14287, Thermo Fisher Scientific) and then were fixed in 10% phosphate-buffered formalin. The sections were next mounted on glass slides with the lumen facing up using Vectashield Antifade Mounting Medium with 4',6-diamidino-2-phenylindole (Catalog #: H-1200, Vector Laboratories, Inc., Burlingame, CA, USA). The fluorescence of SNARF-1 was excited at 570 nm and the emitted light was collected with a longpass filter of 600 nm, and the fluorescence of 4',6-diamidino-2-phenylindole (DAPI) was excited at 360 nm and the emitted light was collected with a band filter of 400–450 nm. Blue DAPI fluorescence was used to focus on the endothelium layer of the coronary strips, and then the red fluorescence of SNARF was used to identify the adhered monocytes. The number of adherent monocytes was determined using the Till Photonics single-cell fluorescence imaging system by counting the red fluorescent cells attached to the surface of the endothelium. Each value represents an average of the adherent monocyte counts observed in three different images for each strip.

**Pig macrophage culture and differentiation**

Freshly isolated peripheral blood mononuclear cells were suspended in the macrophage growth medium and were then plated on plastic 24-well plates (BD Biosciences, Thermo Fisher Scientific). The macrophage growth medium consisted of RPMI-1640 (Gibco, Thermo Fisher Scientific), supplemented with 15% L929 conditioned medium, 15% horse serum, 5% FBS, 1 mM glutamine, 50 units penicillin, and 50 μg/ml streptomycin. Cells were cultured for 3 days, and on day 3, the old medium and floating cells were removed from the wells. The attached cells were washed one time with PBS and then with fresh macrophage growth medium and cultured further for an additional 2 days. On day 5, the old macrophage growth medium was removed leaving 0.5 ml in each well, and then fresh macrophage growth medium was added to the wells. On day 7, the differentiated macrophages were used for total mRNA isolation as described later. The L929 conditioned medium was prepared as follows. L929 cells (ATCC) were grown in complete DMEM supplemented with 10% fetal bovine serum, 50 units penicillin, and 50 μg/ml streptomycin until 90% confluence for four days. The supernatant was collected in 50 ml centrifuge tubes, centrifuged at 10,000 g to remove cell debris and after filtration (20 μm) used as the conditioned L929 medium.

**Real-time quantitative PCR (RT-qPCR)**

Total RNA from snap-frozen Lean pig coronary artery rings organ-cultured for 36 h was isolated using the Trizol method (Invitrogen) with a subsequent deoxyribonuclease treatment step to eliminate any possible traces of the genomic DNA in the total RNA. The Bio-Rad iScript cDNA synthesis kit was utilized to reverse-transcribe cDNA using total RNAs as templates. Total RNA from macrophage cultures was isolated using the RNeasy Mini kit (Qiagen) according to manufacturer’s instructions. The superscript VILO cDNA synthesis kit was used to reverse-transcribe cDNA using total RNAs as templates. The Applied Biosystems (Foster City, CA, USA) 7500 Real-Time PCR System was utilized to perform RT-qPCR. The data were quantified using the standard ΔΔCt method. The endogenous controls (18S ribosomal (r) RNA or β2 micro globulin) were amplified with TaqMan Universal PCR Master Mix (Applied Biosystems), whereas TRPC1 and TRPC6 were amplified using SYBR Green Master mix (Applied Biosystems). The sequences of primer sets were as follows: 5'-TAGCAACAGCCCACTGGT-3' (TRPC6, forward), 5'-AGGCCCTTCTCAGAAGGC-3' (TRPC6, reverse), 5'-CGATGTTCCTTTAGTGCAGT-3' (β2 micro RNA, forward), and 5'-GGTCCAAGATTT CACCTT-3' (18S rRNA, reverse). The RT\(^2\) qPCR primer assays for TRPC1 and β2 micro globulin were from QIA-GEN (Mansfield, MA, USA; Cat.#: PPS03885A and Cat.# PPS00376A, respectively). The RT\(^2\) qPCR primer sequences were not disclosed by the manufacture. The no-reverse-transcriptase control was performed and was negative.

**Chemicals**

All inorganic salts and buffers, histamine, and α-smooth muscle actin antibodies were purchased from Sigma (St. Louis, MO, USA). The TRPC6 antibody was from Santa Cruz (Dallas, TX, USA). Fura-2AM, Vectashield Antifade Mounting Medium, and Carboxy SNARF-1 were from Thermo Fisher Scientific.

**Statistical analysis**

All data are presented as mean ± standard error of the mean (SEM). The unpaired t test was used to determine whether there is a statistically significant difference between the two data sets with normally distributed populations and equal variances. The one-way ANOVA test followed by the post hoc all pairwise multiple
comparison Student–Newman–Keuls test was used to
determine whether there was a significant difference
between the means of multiple experimental groups
with normally distributed populations and equal variances. The
Kruskal–Wallis analysis of variance on ranks test fol-
lowed by the post hoc all pairwise multiple comparisons
Dunn’s test was used to compare the data sets with non-
normally distributed populations and unequal variances.
The two-way ANOVA test followed by the Student–
Newman–Keuls post hoc all pairwise multiple comparison
test was used to compare the experimental groups affected
by two different factors when the data sets were normally
distributed populations with equal variances. The Sig-
maPlot 13 software package (Systat Software Inc., San
Jose, CA, USA) was used to perform the statistical
analyses. The results were considered significantly dif-
f erent if the $p$ value was <0.05.

**Results**

To investigate the effect of long-term spironolactone
treatment on TRPC expression and coronary pathology in
metabolic syndrome pigs, Ossabaw miniature pigs were
subdivided into three groups: Lean, metabolic syndrome
(MetS), and metabolic syndrome treated with spironolac-
tone (MetS-SN). All of the pigs were initially raised on the
standard chow to an age of about 6–8 months. The pigs
were then fed diets according to their group for an addi-
tional 7–9 months. The diets were as follows: the same
standard chow (Lean group), an atherogenic diet (1 kg/day,
MetS group), or the atherogenic diet supplemented with
spironolactone (3 mg/kg body weight/day, MetS-SN
group).

**Metabolic phenotype**

The pigs from the MetS and MetS-SN groups were obese
as compared to the Lean group with significantly greater
body weight (Table 1). However, there was no significant
difference between the average body weights in the MetS
and MetS-SN groups. MetS pigs exhibited elevated mean
systolic blood pressure, but it was not significantly differ-
ent from that observed in the MetS-SN group. The values
of mean diastolic blood pressure, serum sodium, serum
potassium, and serum triglycerides were not significantly
different among the tested groups (Table 1). Pigs from the
MetS and MetS-SN groups presented with impaired glu-
cose tolerance when compared to Lean pigs (Fig. 1a).
Blood glucose levels were higher in MetS and MetS-SN
pigs when compared with Lean pigs at the 5, 10, 20, and
30 min time points following a bolus of intravenous glu-
cose of 1 g/kg of body weight (Fig. 1a). The mean total
plasma cholesterol concentration was markedly elevated in
the MetS and MetS-SN groups as compared to that
observed in the Lean group (Lean: 69 ± 5 mg/dl, $n = 12$;
MetS: 613 ± 72 mg/dl, $n = 10$; MetS-SN: 385 ± 50 mg/
dl, $n = 9$; Fig. 1b). There was no difference between the
total plasma cholesterol concentrations observed in the
MetS and MetS-SN groups, indicating that spironolactone
treatment did not significantly affect the total plasma
cholesterol levels in the pigs.

**Coronary artery disease**

Collagen content is an important characteristic of
atherosclerotic plaques, as increased collagen deposits are
linked to coronary stenosis and increased plaque stability.
Therefore, we investigated whether collagen deposition in
the coronary artery medial layer and atheroma varied
among the experimental groups. The Masson’s trichrome
staining showed that collagen content was significantly higher
in the medial layer of MetS pigs (36.8 ± 3.5%,
$n = 10$) compared to Lean pigs (15.1 ± 1.8%,
$n = 6$; Fig. 1c–h; Supp. Figure 1). Long-term spironolactone
treatments significantly decreased total collagen deposition
in the medial layer (20.9 ± 3.2%, $n = 6$; MetS-SN group).
Atheroma collagen content was significantly decreased in
MetS-SN pigs compared to that in MetS pigs (Lean
atheroma 29.9 ± 10.3%,
$n = 3$; MetS-SN atheroma
52.2 ± 13.3%,
$n = 4$; MetS atheroma 77.5 ± 3.8%,
$n = 6$; Fig. 1h).

To obtain an initial assessment of the extent of
atherosclerosis in coronary arteries of Lean, MetS, and
MetS-SN groups, we first performed IVUS measurements
(Fig. 2). Lean coronary arteries presented only minimal
atherosclerosis (Fig. 2a, Lean). Conversely, MetS coronary
arteries exhibited increased atherosclerosis (Fig. 2a).
The percent wall coverage was significantly higher in coronary
arteries from left anterior descending (LAD) and right
coronary arteries (RCA) in MetS pigs compared to Lean
pigs (RCA: Lean 6.8 ± 1.1%,
$n = 4$; MetS 37.4 ± 7.2%,
$n = 7$; LAD; Lean 5.7 ± 1.5%,
$n = 5$; MetS
32.3 ± 6.4%,
$n = 7$; Fig. 2b, c). Long-term spironolactone
treatment significantly reduced atherosclerosis in the LAD
MetS-SN group (the percent wall coverage: 16.1 ± 4.5%
for Met-SN LAD, $n = 6$, and 22.5 ± 5.8% for Met-SN
RCA, $n = 6$; Fig. 2c). However, likely due to the limited
number of pigs examined with IVUS no significant dif-
ference was detected between the RCA-MetS and Met-SN
groups. However, histology to assess the degree of
atherosclerosis was performed on all pigs including those
MetS pigs that died during the study. The mean percent
wall coverage was significantly increased in MetS RCAs as
compared to that in Lean RCAs and significantly reduced
in MetS-SN RCAs as compared to the mean value.
observed in pigs from the MetS group (RCA-MetS: 60.2 ± 9%, n = 13; RCA-Lean: 13.1 ± 3.3%, n = 9; and RCA-MetS-SN: 28.2 ± 7.3%, n = 9; Fig. 3). These data indicate that long-term spironolactone treatment decreases MetS-associated collagen deposition and the degree of atherosclerosis.

**MetS coronary arteries exhibit increased histamine-induced contractions and intracellular Ca\(^{2+}\) transients**

Isometric tension measurements were performed to assess the ex vivo contractility of coronary arteries from the three tested groups. Coronary artery rings across the groups exhibited similar concentration-dependent contraction stimulated by KCL-mediated depolarization of smooth muscles (Fig. 4a, b). The EC\(_{50}\) values were as follows: Lean: 28 ± 2 mM; MetS: 29 ± 2 mM; MetS-SN: 33 ± 2 mM. Histamine (10\(^{-7}\) to 10\(^{-4}\) M) also induced concentration-dependent contractions of coronary artery rings from all of the three tested groups (Fig. 4c, d); and contractions induced by 10, 30, and 100 μM histamine were significantly increased in coronary arteries from MetS pigs as compared to those from Lean and MetS-SN pigs (for 10 μM—Lean: 1.05 ± 0.05, n = 13 vs. MetS 1.23 ± 0.1, n = 7; for 30 μM—Lean: 1.10 ± 0.07, n = 13 vs. MetS: 1.65 ± 0.14, n = 7; MetS vs. MetS-SN: 1.3 ± 0.06, n = 9; for 100 μM—Lean: 1.26 ± 0.04, n = 13 vs. MetS: 1.85 ± 0.15, n = 7; MetS vs. MetS-SN: 1.38 ± 0.06, n = 9). However, the EC\(_{50}\) values for histamine (Lean 6.9 ± 1.1 μM; MetS 3.5 ± 0.6 μM; MetS-SN 5.9 ± 1.5 μM; Fig. 4d) were not significantly different among the tested groups.

We also employed front-surface fluorometry to assess intracellular Ca\(^{2+}\) ([Ca\(^{2+}\)]\(_i\)) changes in response to KCL and histamine in fura-2 loaded rings (Fig. 5a). The peak amplitudes of 70 mM KCl-stimulated Ca\(^{2+}\) influx in Lean, MetS, and MetS-SN groups did not differ significantly (Lean 0.10 ± 0.02, n = 7; MetS 0.06 ± 0.01, n = 9; MetS-SN 0.08 ± 0.02, n = 6). Conversely, the peak amplitudes of 40 μM histamine-induced Ca\(^{2+}\) influx were significantly larger in MetS coronary artery rings (1.1 ± 0.2, n = 9) than in Lean (0.4 ± 0.07, n = 7), and MetS-SN (0.4 ± 0.1, n = 6; Fig. 5b–f). The mean steady state values of histamine-induced [Ca\(^{2+}\)]\(_i\) increases were greater in MetS rings (0.56 ± 0.10, n = 6) than in Lean rings (0.15 ± 0.03, n = 4) and MetS-SN rings (0.18 ± 0.03, n = 5; Fig. 5b–f). These data indicate that besides reducing atheroma formation, long-term spironolactone treatments attenuate histamine-induced [Ca\(^{2+}\)]\(_i\) changes and vasoconstriction that is associated with MetS.

**MetS-associated coronary artery endothelial dysfunction can be prevented by long-term treatment with spironolactone**

MetS coronary arteries are known to exhibit endothelial dysfunction. Indeed, Fig. 6a shows that concentration-dependent bradykinin-induced dilations were significantly decreased in MetS pig coronary arteries pre-contracted with 100 μM histamine (n = 10) as compared to those from Lean pigs (n = 7). Long-term treatment with spironolactone significantly improved endothelial function in MetS pig coronary arteries pre-contracted with 100 μM histamine (n = 6, Fig. 6a). Figure 6b shows that similar results were obtained in 30 mM KCL pre-contracted coronary artery rings (MetS, n = 5; Lean, n = 8, and MetS, n = 5). MetS coronary artery rings presented with markedly impaired bradykinin-induced dilations as compared to 30 mM KCL pre-contracted Lean pig coronary artery rings, and spironolactone-treated MetS-SN pigs showed significantly improved bradykinin-induced dilations.

---

**Table 1** Phenotypic characteristics of pig groups

|                | Lean     | MetS     | MetS-SN   | P values                       |
|----------------|----------|----------|-----------|--------------------------------|
| Number of animals | 7        | 7        | 6         |                                |
| Body weight (kg) | 49 ± 4   | 84 ± 3   | 79 ± 3    | <0.001                         |
| SBP (mmHg)      | 131 ± 3  | 151 ± 3  | 138 ± 7   | 0.01                           |
| DBP (mmHg)      | 75 ± 4   | 84 ± 4   | 71 ± 4    | NS                             |
| Triglycerides (mg/dl) | 28.9 ± 6.3 | 41.7 ± 13.0 | 30.7 ± 3.3 | NS                             |
| Sodium (mEq/l)  | 136.3 ± 1.0 | 139.4 ± 0.7 | 138.2 ± 1.2 | NS                             |
| Potassium (mEq/l) | 4.9 ± 0.7 | 4.4 ± 0.3 | 4.3 ± 0.2 | NS                             |

The one-way ANOVA test followed by the Student–Newman–Keuls post hoc test. *L* lean, *MetS* metabolic syndrome, *MetS-SN* metabolic syndrome group treated with spironolactone, *SBP* and *DBP* systolic and diastolic blood pressure, *NS* no significant different.
Pattern of TRPC immunostaining in the coronary artery wall

To determine whether the MetS-associated increases in TRPC1 and TRPC6 protein expression occur locally or globally within the coronary wall immunohistochemical studies were performed. TRPC1 immunostaining was weak in the medial layer of all tested groups (Fig. 7a). The mean immunostaining density ratios of adventitia over media were as follows: 1.08 ± 0.03 (n = 4), 1.10 ± 0.02 (n = 9) and 1.06 ± 0.02 (n = 5), for Lean, MetS, and MetS-SN groups, respectively (Fig. 7b). Conversely, TRPC1 immunostaining was significantly greater in MetS atheromas than in MetS medial layer (MetS atheroma: 1.77 ± 0.23, n = 7). Spironolactone treatment significantly decreased TRPC1 immunostaining in the atheromas (MetS-SN atheroma 1.11 ± 0.12, n = 5, Fig. 7b). These data indicate that in Lean pigs, TRPC1 expression is low in the coronary artery wall with a particular localization to the medial layer. The channel’s protein expression is not
significantly increased in the medial layer of MetS pigs. However, TRPC1 is highly expressed in the atheromas of MetS pigs.

In the coronary artery wall, TRPC6 immunostaining was localized to the medial layer in all the tested groups. Its density was similarly low in both adventitia and atheroma of MetS and MetS-SN pigs (MetS: 1.02 ± 0.06, n = 6; MetS-SN: 1.10 ± 0.07, n = 4, Fig. 7c). But, TRPC6 immunostaining density was much stronger in the medial layer of MetS pigs as compared to that in the Lean and MetS-SN medial layers, with the TRPC6 staining ratios of adventitia/medial being as follows: Lean 1.13 ± 0.08 (n = 6) vs. MetS 1.56 ± 0.09 (n = 9), and MetS vs. MetS-SN 1.19 ± 0.11 (n = 6). These data indicate that TRPC6 expression is increased in the medial layer, but not in atheromas of MetS coronary artery wall; and that TRPC6 upregulation in the MetS medial layer is diminished by spironolactone treatment (Suppl. Figure 2).
Increased TRPC expression correlates with coronary artery pathology

To determine whether there is an association between increased TRPC expression and coronary artery pathology, we performed the Pearson Product Moment Correlation analysis (SigmaPlot 13). TRPC6 expression and histamine-induced active tension (Fig. 4) as well as TRPC1 expression and atherosclerosis associations (Fig. 3) were analyzed. We found that the Pearson Product Moment correlation coefficients amounted to 0.78 and 0.86 for the TRPC6-active tension data sets and the TRPC1-percent wall coverage data sets, respectively, indicating a strong correlation between these pairs of variables (Fig. 8).

TRPC1 immunostaining is predominantly found in macrophage-rich atheroma areas

The fact that the strongest TRPC1 immunostaining was observed in atheromas rather than in the medial layer prompted us to hypothesize that TRPC1 expression may be localized to the proliferating SMCs in atheromas. To test this hypothesis, SMCs in the adjacent MetS sections were stained with an α-smooth muscle actin (SMA) antibody. Unexpectedly, we found that although TRPC1 immunostaining was present in some neointimal SMCs of atheromas, it was stronger in the plaque areas having less SMA immunoreactivity (Fig. 9; Suppl. Figure 3). Therefore, we next stained the adjacent sections of coronary arteries from MetS pigs for markers of macrophages (CD163 and CD33) and T cells (CD3) and compared staining patterns with that of TRPC1. It was noticeable that TRPC1 staining was predominantly observed in the segments of atheromas with robust CD163 and CD33 immunostaining, and scant CD3 immunostaining (Fig. 9a; Suppl. Figure 3), indicating atheroma’s TRPC1 immunostaining is not only found in neointimal SMCs but also strongly associated with macrophages. Figure 9b shows the phenotyping of atherosclerotic lesions. The mean % content of α-SMA, CD163, CD33, and CD3 immunoreactivities amounted to 37.5 ± 5.6, 58.8 ± 11.6, 45.7 ± 6.7, and 9.4 ± 3.4%, respectively (n = 6, in each case).

In vivo dominant-negative TRPC6 cDNA construct delivery

The correlation between TRPC6 expression and histamine-induced coronary contractions prompted us to investigate whether decreasing coronary TRPC6 activity would reduce histamine-induced [Ca^{2+}], transients in MetS pig coronary arteries. In vivo gene transfer of the dominant-negative (DN) TRPC6 construct was performed into coronary artery walls in beating hearts. Figure 10a shows sample angiographic images obtained during the intracoronary
placement of the injection and electroporation catheters inside of a circumflex coronary artery in vivo (see “Materials and methods” for details). We found that electroporated coronary arteries were fragile (Fig. 10b), complicating isometric tension experiments with the electroporated rings. Therefore, we focused on fluorescence imaging to compare the peak amplitudes of histamine-induced [Ca$^{2+}$]$_i$ transients in the in vivo injected/electroporated and control rings adjacent to the electroporated area, which were isolated from the same pig. [Ca$^{2+}$]$_i$ transients are critical for triggering coronary smooth muscle cell contractions. In control experiments, the Lean pig coronary artery rings that were in vivo injected with pcDNA3 empty vector and then intracoronary

Fig. 5  Front-surface fluorometry in coronary artery rings loaded with Fura-2. a Fluorescence images of a coronary artery ring from a Lean pig, which were obtained at an excitation wavelength of 380 nM (left panel control; middle panel under 70 mM KCl; right panel under 40 μM histamine). b–d Sample traces of [Ca$^{2+}$]$_i$ changes in coronary artery rings from Lean (a), MetS (b), and MetS-SN (e) rings are shown. KCl and histamine (40 μM) were added at the times indicated with the horizontal bars. e Summary of data for the peak (blue vertical line in b–d) values of [Ca$^{2+}$]$_i$ responses to histamine (40 μM) normalized to the peak of KCl response in the tested rings. *P < 0.05; **P < 0.01. The one-way ANOVA test followed by the Student–Newman–Keuls post hoc test. f Steady state phase (red vertical line in b–d) values of [Ca$^{2+}$]$_i$ responses to histamine (40 μM) normalized to the peak of KCl response in the tested rings. The steady state value was calculated at 3.3 min after the peak value of the histamine response was reached. Kruskal–Wallis one-way analysis of variance on ranks followed by the Dunn’s post hoc test. *P < 0.05; **P < 0.01. His histamine.

Fig. 6  Assessment of endothelial function in coronary arteries from the three tested groups using isometric tension measurements. a, b Concentration–response curves for bradykinin-induced dilation in histamine- (a) and 30 mM KCl- (b) pre-contract coronary artery rings from Lean, MetS and MetS-SN pigs. Sample traces of bradykinin-induced coronary ring dilations are shown in insets. *P < 0.05, **P < 0.01, ***P < 0.001, *MetS vs. Lean; #P < 0.05, ##P < 0.01, ###P < 0.001, #MetS vs. MetS-SN. The two-way ANOVA test followed by the Student–Newman–Keuls post hoc test.
electroporated exhibited normalized histamine-induced $[Ca^{2+}]_i$ transients that were not significantly different from those observed in non-electroporated rings (Fig. 10c, e). While the empty vector had no effect, we confirmed that there was no non-specific effect of the electroporation and instrumentation by over expressing another histamine-regulated channel, TRPC5. The Lean pig coronary artery rings in vivo injected/electroporated with mTRPC5-pcDNA3 exhibited significantly greater normalized histamine-induced $[Ca^{2+}]_i$ transients compared to those observed in pcDNA3-injected/electroporated rings (Fig. 10c, e). Gd$^{3+}$ (100 μM) caused only small or no inhibition of histamine-induced $[Ca^{2+}]_i$ transients in the tested rings (Fig. 10c), likely due to poor permeability of pig coronary artery wall to Gd$^{3+}$. Importantly, we found that normalized histamine-induced $[Ca^{2+}]_i$ transients were significantly decreased in MetS pig coronary artery rings in vivo injected/electroporated with a dominant-negative (DN) TRPC6 construct as compared to those observed in control rings (Fig. 10d, e).

**Fig. 7** Assessment of TRPC expression pattern in the coronary artery wall. **a** Sample images of immunohistochemical staining of coronary artery ring sections from the tested groups. The upper row of images shows controls in which no primary antibody (AB) was added. The middle row of images show the sections stained with the TRPC1 antibody, whereas the lower row of images shows the sections stained with the TRPC6 antibodies. The medial layer is indicated with black arrows in TRPC1 images and white arrows in the TRPC6 images. The dotted lines show the borders between the coronary wall layers. Scale bars 100 μm. A adventitia, M media, I intima, L lumen. **b, c** Comparison of mean normalized density of immunostaining in the tested groups for TRPC1 and TRPC6, respectively. *P < 0.05; **P < 0.01. The two-way ANOVA test followed by the Student–Newman–Keuls post hoc test.
Aldosterone treatment increases histamine-induced contractions of organ-cultured coronary arteries in a mineralocorticoid receptor-dependent manner

We previously reported that TRPC6 expression was upregulated in coronary arteries of MetS pigs [16]; and that plasma aldosterone was elevated in MetS Ossabaw pigs [2]. It was also reported that that aldosterone treatment leads to increased TRPC6 expression in arterial smooth muscle cells [3]. To provide further evidence supporting the hypothesis that TRPC6 upregulation correlates with increased pig coronary artery contractility, we next employed the in vitro organ-culture model. Using quantitative RT-PCR, we confirmed that aldosterone treatment increased TRPC6 expression in organ-cultured Lean pig coronary artery rings (Suppl. Figure 4). Then, we assessed whether aldosterone treatment would increase coronary contractility, and whether inhibition of the mineralocorticoid receptor by spironolactone would prevent this effect. Four groups of Lean coronary artery rings were initiated as follows: (1) DMSO (vehicle control) group; (2) aldosterone (100 nM) group; (3) aldosterone (100 nM) plus spironolactone (10 μM) group; and (4) spironolactone (10 μM) group. The rings (3 mm long) were organ-cultured for 7 days without fetal bovine serum to avoid any possible contribution of growth factors and other vasoactive molecules present in the fetal bovine serum; and the histamine-induced contractility of the rings was measured using a wire myograph. Figure 11 shows that the contractions induced by 10, 100, 300, and 1000 μM histamine were significantly stronger in both intact (Fig. 11a, n = 7) and denuded (Fig. 11b, n = 6) rings treated with aldosterone as compared to those treated with DMSO and spironolactone. Aldosterone-induced increases in coronary contractility were comparable in both denuded and intact rings, arguing against any role of the endothelium in mediating the aldosterone-induced contractility changes. Importantly, the “aldosterone plus spironolactone”-treated rings exhibited contraction amplitudes similar to those observed in the DMSO-treated and spironolactone-treated groups, but significantly smaller than those found in the aldosterone-treated group. These data indicate that inhibition of the mineralocorticoid receptor by spironolactone prevents aldosterone-dependent upregulation of histamine-induced coronary contractility.

Monocytes adhesion to the endothelium is regulated by aldosterone in a mineralocorticoid receptor-dependent manner

The adhesion of monocytes to the endothelium of coronary arteries and their subsequent extravasation constitute the earliest steps of atherosclerosis progression. To investigate the role of aldosterone in regulating monocyte adhesion to the endothelium of Lean pig coronary arteries, we again used the organ-cultured coronary arteries. Again, four test groups were initiated and treated for 48 h with (1) DMSO; (2) aldosterone; (3) aldosterone plus spironolactone; and (4) spironolactone. Coronary artery strips were used in these experiments. Peripheral blood monocytes were isolated using flow cytometry. Figure 12a shows that the degree of monocyte enrichment exceeded 75%, about five times higher than the initial monocyte count (16.1%). The pig monocytes exhibited low levels of adhesion to the endothelium of DMSO and spironolactone-treated coronary arteries. Again, four test groups were initiated and treated for 48 h with (1) DMSO; (2) aldosterone; (3) aldosterone plus spironolactone; and (4) spironolactone. Coronary artery strips were used in these experiments. Peripheral blood monocytes were isolated using flow cytometry. Figure 12a shows that the degree of monocyte enrichment exceeded 75%, about five times higher than the initial monocyte count (16.1%). The pig monocytes exhibited low levels of adhesion to the endothelium of DMSO and spironolactone-treated coronary arteries. Only a few adherent cells were observed in these experiments (Fig. 12b). Conversely, aldosterone treatment increased monocytes adhesion to coronary artery strips by 2.4 ± 0.6 fold. Spironolactone treatment potently inhibited aldosterone-mediated monocyte adhesion to the coronary endothelium (Fig. 12c).
TRPC1 is expressed in macrophages differentiated from pig peripheral blood monocytes

We next investigated whether the expression level of TRPC1 is distinct in differentiated macrophages obtained from the Lean, MetS, and MetS-SN groups. Pig peripheral blood mononuclear cells were isolated and differentiated into macrophages by culturing in the presence of the L929 conditioned medium. TRPC1 mRNA expression was quantified in the differentiated macrophages. TRPC1 was equally expressed in the macrophages across the tested groups (Suppl. Figure 5).
Discussion

In this study, we investigated the roles of TRPC channels in MetS coronary arteries and determined whether spironolactone exhibits any anti-atherosclerotic potential in the Ossabaw pig model of diet-induced metabolic syndrome. Our principal new findings include: (1) TRPC1 is highly expressed in the macrophages residing in the atheroma of metabolic syndrome coronary arteries; (2) elevated TRPC6 is mostly found in the contractile coronary SMCs of the medial layer but not in proliferative neointimal SMCs or macrophages of atheroma; (3) histamine-induced $[\text{Ca}^{2+}]_i$
transients are significantly decreased in the MetS coronary artery segments after in vivo targeted DN-TRPC6 delivery; and (4) long-term spironolactone treatment significantly decreases the protein expression level of TRPC1 and TRPC6 channels in coronary arteries associated with reduced native atherosclerosis and vasoconstriction.

Upregulation of TRPC1 expression in neointimal SMCs is critical for occlusive coronary artery disease progression in the pig model of neointimal hyperplasia after vascular injury via balloon angioplasty [33]. Surprisingly, we found that in contrast to the vascular injury model, the diet-induced pig model of MetS-associated atherosclerosis showed that the TRPC1 protein is predominantly expressed in macrophages residing in the cores of atheromas (Suppl. Figure 3), although TRPC1 immunostaining is also observed in some neointimal SMCs. Thus, our data underscore the importance of macrophage TRPC1 expression in coronary atherosclerosis in MetS.

Unlike TRPC1, TRPC6 expression was greater in the medial layer of MetS coronary arteries. Both histamine-induced contractions and \([\text{Ca}^{2+}]_i\) transients are increased in coronary arteries from the MetS group that exhibited an increased TRPC6 protein level in the medial layer. These data support our overall hypothesis that higher TRPC6 expression in the smooth muscle layer correlates with increased coronary contractility.

Coronary arteries from spironolactone-treated MetS pigs exhibited milder atherosclerosis and reduced collagen content and spasticity compared to age-matched control MetS coronary arteries did. Thus, our findings provide evidence that spironolactone attenuates MetS-associated coronary atherosclerosis. These data are consistent with two previous reports indicating that another mineralocorticoid receptor inhibitor, eplerenone, and aldosterone synthase inhibitors are effective at slowing plaque growth in a mouse ApoE-/- model of aortic atherosclerosis [20, 31] and a recent initial clinical study reporting that spironolactone may decrease atherosclerosis in humans [37]. Importantly, in this study, we utilized the diet-induced pig model of MetS-associated coronary atherosclerosis, which better represents the human setting than the mouse ApoE knock-out/cholesterol handling-dependent model of atherosclerosis [34].

Previously, we reported that TRPC1 and TRPC6 expression is markedly elevated in metabolic syndrome pig coronary arteries [16]. The promoter regions of TRPC1 and TRPC6 possess half-site glucocorticoid/mineralocorticoid response elements [26] driving the expression of these TRPC channels in metabolic syndrome, characterized by elevated plasma aldosterone [2]. Our new data indicate that one of the mechanisms underlying spironolactone’s beneficial actions in atherosclerosis may include decreased TRPC channel expression in the coronary artery wall. Specifically, spironolactone-dependent reduction of TRPC1 in atheroma was strongly associated with a marked decrease of atherosclerosis, whereas spironolactone-dependent downregulation of medial TRPC6 was associated with decreased histamine-induced contractility and reduced \([\text{Ca}^{2+}]_i\) transients in the medial layer. Consistently, we found that in vivo targeted delivery of the DN-TRPC6 construct into the MetS coronary artery wall using an in vivo intracoronary electroporation approach resulted in decreased histamine-induced \([\text{Ca}^{2+}]_i\) transients in the MetS coronary artery segments. Collectively, this supports the hypothesis that TRPC6 upregulation leads to increased coronary contractility. However, the limitation of this study...
is that coronary artery reactivity is assessed only using the in vitro approaches in coronary artery rings. Although these coronary artery ring data were important for establishing the critical correlation between TRPC6 expression and coronary artery contractility in diet-induced metabolic syndrome, future experiments will be needed to confirm the present in vitro reactivity results using the in vivo coronary histaminergic provocation test.

Macrophage accumulation in the coronary intima plays a critical role during atherosclerotic plaque formation and growth [14, 30]. However, the mechanism of how macrophage TRPC1 expression promotes coronary atherosclerosis progression remains unclear. We found that TRPC1 and macrophage immunostaining were pronounced in MetS atheromas and reduced in MetS-SN atheromas. Since elevated aldosterone is a feature of metabolic syndrome, we hypothesized that higher TRPC1 immunostaining in MetS atheromas may be due to an aldosterone-dependent increase in monocyte adhesion to the coronary endothelium and that spironolactone may decrease monocyte adhesion. Indeed, it was reported that endothelial intercellular adhesion molecule (ICAM1) gene and protein expression was upregulated in human coronary artery endothelial cells by aldosterone in a mineralocorticoid receptor-dependent manner [7], leading to increased adhesion of leukocytes. To test our hypothesis, we used the organ-cultured coronary artery rings from Lean pigs. We treated the organ-cultured rings with aldosterone and found that aldosterone did increase adhesion of monocytes to pig coronary artery endothelium (Fig. 12). Importantly, spironolactone antagonized this effect. Therefore, we speculate that spironolactone may slow down atherosclerosis progression by reducing TRPC1-positive monocyte adhesion to the coronary endothelium and their subsequent extravasation.

Spironolactone inhibits microsomal cholesterol 7α-hydroxylase activity and increases bile salt-independent bile flow (choleresis) in the liver, resulting in increased cholesterol excretion into the bile [42]. However, subsequent clinical studies revealed controversial findings, indicating that spironolactone may or may not affect total cholesterol level in human subjects [9, 17, 39, 48]. Elevated levels of plasma cholesterol are strongly associated with atherosclerosis development [4]. Therefore, we investigated spironolactone’s effect on total plasma cholesterol level in the Ossabaw pig model. Our data indicate that spironolactone does not significantly reduce plasma cholesterol concentration in the Ossabaw pig model of MetS. Therefore, we propose that the observed effects of spironolactone in our study are unlikely to be due to a reduction of total plasma cholesterol concentration in the MetS-SN pigs.

Fig. 12 Monocytes adhesion assay. a Representative images show flow cytometry sorts of peripheral blood mononuclear cells before and after monocyte enrichment. The cells were stained with pig CD3 and CD172a antibodies. Images show a marked increase in monocyte populations and T-cell depletion. b Images of monocytes adhesion to the endothelium after an incubation for 2 h with coronary artery strips pretreated with DMSO, aldosterone (Ald), aldosterone plus spironolactone (Ald + SN) and spironolactone (SN) for 48 h. The monocytes were loaded with the dye of SNARF-1 and seen as red spots. Bar 200 μm. c Summary for data shown in b. **P < 0.01. The one-way repeated measures ANOVA test followed by the Holm–Sidak post hoc test
Long-term spironolactone treatment in MetS pigs prevents MetS-associated endothelial dysfunction. These data are consistent with a recent report that eplerenone, another antagonist of the mineralocorticoid receptor, prevented endothelial dysfunction associated with diet-induced obesity in C57BL/6 mice [44]. Schafer et al. [44] provided evidence that eplerenone-mediated inhibition of endothelial mineralocorticoid receptors results in a reduction of pro-oxidative p22phox and p40phox gene expression and an increase in expression of antioxidative genes, such as glutathione peroxidase-1 and superoxide dismutase, counteracting aldosterone-dependent reactive oxygen species generation in endothelial cells. We speculate that a similar mechanism may underlie spironolactone’s effects in our pig model of metabolic syndrome.

The major physiological function of aldosterone in the human body is to regulate Na\(^+\) and K\(^+\) plasma concentrations. Aldosterone acting via the mineralocorticoid receptor in the principal epithelial cells of the kidney collecting duct causes Na\(^+\) retention, which is important for regulating blood volume. However, excessive aldosterone-dependent Na\(^+\) retention results in hypertension. Spironolactone, a competitive inhibitor of the mineralocorticoid receptors, is widely prescribed to treat hypertension due to the abnormal Na\(^+\) retention by the kidney. In this study, we did find that the mean systolic blood pressure was elevated in the MetS pigs. However, the mean systolic blood pressure in MetS-SN pigs was not significantly different from its mean value in MetS pigs. Given the fact that neither blood pressure nor plasma Na\(^+\) concentration was significantly different in MetS and MetS-SN groups (Table 1), these data argue against the notion that spironolactone action on the kidney underlies the anti-atherosclerotic effect of this drug. We propose that mineralocorticoid receptor antagonism by spironolactone in the coronary artery wall rather than in the kidney contributes to the improvements observed in the MetS-SN group.

The combined reduction in arterial pressure and plasma cholesterol, although both not statistically significant, may synergize to attenuate atheroma. We contend, however, that this combination of systemic factors is unlikely to be the underlying cause for the reduced lesion size. We propose that the direct vascular wall signaling plays the major role in atheroma reduction.

Conclusions

This study demonstrates that long-term mineralocorticoid receptor blockade with spironolactone decreased coronary TRPC expression, atherosclerosis, and hypercontractility in the Ossabaw pig model of metabolic syndrome without impacting obesity or glucose tolerance. Targeted down-regulation of TRPC6 by intracoronary application of a dominant-negative construct provides additional evidence for the key role of TRPC6 in hypercontractility of MetS coronary arteries. TRPC1-positive macrophages present in the coronary artery wall of MetS pigs are associated with advanced atherosclerotic lesions.

Acknowledgements We thank Dr. Jonathan D. Tune for valuable discussions during this project. We thank Mr. James Byrd, Mrs. Brandy Sparks, and Mr. Joshua Sturek for performing the IVGTTs. We also thank Mr. James Byrd for performing the surgical procedures for IVUS and intracoronary gene delivery. We are thankful to Mr. Jerett A. Creed of Cardigant Medical Inc. for providing the intravascular electroporation catheters and sharing with us the technique for gene delivery based on in vivo coronary wall injection with a cDNA construct followed by electroporation. This study was supported by grants from the National Institutes of Health, National Heart, Lung, and Blood Institute (R01HL115140 to AGO; and HL110170, EY023629, EY012601, EY007739 to MGB) and the Fortune-Fry Ultrasound Research Fund of the Department of Cellular and Integrative Physiology, Indiana University School of Medicine (AGO, MS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Compliance with ethical standards

Ethical standards All experimental procedures with animals were approved by the Institutional Animal Care and Use Committee of the Indiana University School of Medicine and fully complied with animal use standards.

Conflict of interest On behalf of all authors, the corresponding author states that there is no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Albert AP, Saleh SN, Large WA (2009) Identification of canonical transient receptor potential (TRPC) channel proteins in native vascular smooth muscle cells. Curr Med Chem 16:1158–1165. doi:10.2174/092986709787581815
2. Alloosh M, Pratt JH, Sturek M, Basile D (2008) Elevated renin and enhanced adrenal steroidogenesis in the Ossabaw swine model of the metabolic syndrome. FASEB J 22:736.7 (Abstract)
3. Bae YM, Kim A, Lee YJ, Lim W, Noh YH, Kim EJ, Kim J, Kim TK, Park SW, Kim B, Cho SI, Kim DK, Ho WK (2007) Enhancement of receptor-operated cation current and TRPC6 expression in arterial smooth muscle cells of deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 25:809–817. doi:10.1097/HJH.0b013e3280418312
4. Bender SB, de Beer VJ, Tharp DL, Bowles DK, Laughlin MH, Merkus D, Duncker DJ (2016) Severe familial
hypercholesterolemia impairs the regulation of coronary blood flow and oxygen supply during exercise. Basic Res Cardiol 111:61. doi:10.1007/s00395-016-0579-9

5. Bernini G, Galetta F, Franzoni F, Bardini M, Taurino C, Bernardini M, Ghiaidoni L, Bernini M, Santoro G, Salvetti A (2008) Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens 26:2399–2405. doi:10.1097/JHJ.0b013e3282c87b2d

6. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Bovet P, Frick M, Bovet P, Maillard MR, Elston RC (2006) Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48:239–245. doi:10.1161/01.HY.0000313388.41548.fc

7. Caprio M, Newfell BG, Sala A, Baur W, Fabbri A, Rosano G, Mendelson ME, Jaffe IZ (2008) Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102:1359–1367. doi:10.1161/CIRCRESAHA.108.174235

8. Chakraborty S, Berwick ZC, Bartlett PJ, Kumar S, Thomas AP, Sturek M, Tije ND, Obukhov AG (2011) Bromoelactone inhibits voltage-gated Ca2+ and transient receptor potential canonical channels. J Pharmacol Exp Ther 339:329–340. doi:10.1124/jpet.111.183573

9. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poultner NR (2007) Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49:839–845. doi:10.1161/01.HYP.0000259805.18468.8c

10. Chen X, Egly C, Riley AM, Li W, Tewson P, Hughes TE, Quinn CV, Obukhov AG (2017) Molecular determinants of the sensitivity to Gq/11-phospholipase C-dependent gating, Gβ1γ2 permeability in the transient receptor potential canonical type 5 (TRPC5) channel. J Biol Chem 292:898–911. doi:10.1074/jbc.M116.755470

11. Chen X, Li W, Hiett SC, Obukhov AG (2016) Novel roles for aldosterone synthesis inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. J Hypertens 28:1900–1907. doi:10.1097/HJH.0b013e32832c197

12. Chen X, Li W, Hiett SC, Obukhov AG (2016) Novel roles for aldosterone synthesis inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. J Hypertens 28:1900–1907. doi:10.1097/HJH.0b013e32832c197

13. Chen X, Li W, Hiett SC, Obukhov AG (2016) Novel roles for aldosterone synthesis inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. J Hypertens 28:1900–1907. doi:10.1097/HJH.0b013e32832c197

14. Collet JP, Beygui F, Montalescot G, Doevendans PA, Wassink AM, van Belle E (2013) Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol 167:1929–1935. doi:10.1016/j.ijcard.2012.05.034

15. Collet JP, Beygui F, Montalescot G, Doevendans PA, Wassink AM, van Belle E (2013) Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol 167:1929–1935. doi:10.1016/j.ijcard.2012.05.034

16. Collet JP, Beygui F, Montalescot G, Doevendans PA, Wassink AM, van Belle E (2013) Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol 167:1929–1935. doi:10.1016/j.ijcard.2012.05.034

17. Collet JP, Beygui F, Montalescot G, Doevendans PA, Wassink AM, van Belle E (2013) Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol 167:1929–1935. doi:10.1016/j.ijcard.2012.05.034

18. Collet JP, Beygui F, Montalescot G, Doevendans PA, Wassink AM, van Belle E (2013) Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol 167:1929–1935. doi:10.1016/j.ijcard.2012.05.034

19. Collet JP, Beygui F, Montalescot G, Doevendans PA, Wassink AM, van Belle E (2013) Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol 167:1929–1935. doi:10.1016/j.ijcard.2012.05.034
34. Libby P (2015) Murine “model” monotheism: an iconoclast at the altar of mouse. Circ Res 117:921–925. doi: 10.1161/CIRCRESAHA.115.307523
35. McGraw AP, Bagley J, Chen WS, Galayda C, Nickerson H, Armani A, Caprio M, Carmeliet P, Jaffe IZ (2013) Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. J Am Heart Assoc 2:e000018. doi:10.1002/jaha.100153
36. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ (2010) The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56:1113–1132. doi: 10.1016/j.jacc.2010.05.034
37. Nakhjavani M, Hamidi S, Esteghamati A, Abbasi M, Nosratian-Jahromi S, Pasalar P (2009) Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. Br J Clin Pharmacol 68:634–637. doi: 10.1111/j.1365-2125.2009.03483.x
38. Gilman SG, Smith LN, Stansberry TL, Hayes R (1970) Effects of arterial injury on the reactivity of lung arterioles. J Appl Physiol 28:364–367.
39. Patsolic MA, Poulin JR, Bardin CS, Ewing LL, Switzer RC (1974) Effect of angiotensin II on renal sympathetic nerve activity. J Pharmacol Exp Ther 190:304–312.